Primary endpoint achieved in Ph2 psoriatic arthritis and progression towards Ph3 in ulcerative colitis
Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biotechnology company, focused on the development and commercialization of novel medicines that will improve people's lives.
Galapagos in 10 questions.
We are looking for experienced, open-minded and ambitious colleagues, ready to make a difference in a dynamic working environment. People who dare to think big. You?
We are conducting clinical trials in several inflammatory indications, cystic fibrosis, fibrosis and osteoarthritis.
Thijs Timmers (18) has cystic fibrosis. ‘Impossible’ does not exist in his dictionary.